Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium.

Literature DB >> 8055157

Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium.

K Segers¹, M Ramael, S K Singh, J Weyler, J Van Meerbeeck, P Vermeire, E Van Marck.

Abstract

Immunohistochemical study of bcl-2 protein immunoreactivity in human non-neoplastic mesothelium (44 cases) and in malignant mesothelioma (62 cases) using a murine monoclonal antibody (clone 124) showed cytoplasmic immunoreactivity for bcl-2 protein in five cases of malignant mesothelioma. Non-neoplastic mesothelium was not immunoreactive. Immunoreactivity for bcl-2 protein does not add useful prognostic information in malignant mesothelioma since survival times of bcl-2 positive and bcl-2 negative cases did not differ. Nevertheless, the detection of bcl-2 protein in malignant mesothelioma might be useful for the differentiation from reactive mesothelium.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 1994 PMID： 8055157 DOI： 10.1007/bf00195777

Source DB: PubMed Journal: Virchows Arch ISSN： 0945-6317 Impact factor: 4.064

17 in total

1. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death.

Authors: D M Hockenbery; M Zutter; W Hickey; M Nahm; S J Korsmeyer
Journal: Proc Natl Acad Sci U S A Date: 1991-08-15 Impact factor: 11.205

2. Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma.

Authors: Y Tsujimoto; N Ikegaki; C M Croce
Journal: Oncogene Date: 1987 Impact factor: 9.867

3. Epstein-Barr virus infection and bcl-2 proto-oncogene expression. Separate events in the pathogenesis of Hodgkin's disease?

Authors: G Khan; R K Gupta; P J Coates; G Slavin
Journal: Am J Pathol Date: 1993-11 Impact factor: 4.307

4. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.

Authors: M Colombel; F Symmans; S Gil; K M O'Toole; D Chopin; M Benson; C A Olsson; S Korsmeyer; R Buttyan
Journal: Am J Pathol Date: 1993-08 Impact factor: 4.307

5. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.

Authors: R W Brown; G M Clark; A K Tandon; D C Allred
Journal: Hum Pathol Date: 1993-04 Impact factor: 3.466

6. Immunohistochemical distribution patterns of epidermal growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium.

Authors: M Ramael; K Segers; C Buysse; J Van den Bossche; E Van Marck
Journal: Virchows Arch A Pathol Anat Histopathol Date: 1991

7. bcl-2 protein in non-small-cell lung carcinoma.

Authors: F Pezzella; H Turley; I Kuzu; M F Tungekar; M S Dunnill; C B Pierce; A Harris; K C Gatter; D Y Mason
Journal: N Engl J Med Date: 1993-09-02 Impact factor: 91.245

8. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.

Authors: L H Boise; M González-García; C E Postema; L Ding; T Lindsten; L A Turka; X Mao; G Nuñez; C B Thompson
Journal: Cell Date: 1993-08-27 Impact factor: 41.582

9. Immunoreactivity for the beta chain of the platelet-derived growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium.

Authors: M Ramael; C Buysse; J van den Bossche; K Segers; E van Marck
Journal: J Pathol Date: 1992-05 Impact factor: 7.996

10. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.

Authors: G Cattoretti; M H Becker; G Key; M Duchrow; C Schlüter; J Galle; J Gerdes
Journal: J Pathol Date: 1992-12 Impact factor: 7.996

4 in total